Protagenic Therapeutics, Inc. Files Form 8-K: Key Details for Investors
Key Points from the Filing
- Form Type: 8-K (Current Report)
- Date of Report (Earliest Event Reported): February 3, 2026
- Company Name: Protagenic Therapeutics, Inc.
- Trading Symbol: PTIX
- Exchange: OTC Markets
- SEC File Number: 001-12555
- Business Address: 149 Fifth Avenue, Suite 500, New York, NY 10010
- Company Phone: (212) 994-8200
- Securities Registered: Common Stock (PTIX), Common Stock Warrants (PTIXW)
- Emerging Growth Company Status: The company is not an emerging growth company
- Previous Company Names: Atrinsic, Inc.; New Motion, Inc.; MPLC, Inc.
Details Relevant for Shareholders
-
No Announced Corporate Actions or Material Events:
Based on the content of this 8-K filing, there is no disclosure of any new business developments, acquisitions, divestitures, changes in control, material agreements, or other significant events that are typically price-sensitive or could affect the value of PTIX shares. The filing is primarily administrative and appears to serve as a routine compliance update required by the SEC. -
No Written, Soliciting, or Tender Offer Communications:
The company confirmed that this 8-K is not being used for any written communications under Rule 425 of the Securities Act, nor is it a vehicle for soliciting material, nor related to any pre-commencement tender offers. This further supports the conclusion that there are no major strategic or financial moves being disclosed at this time. -
Common Stock and Warrants Still Listed:
The only securities noted as registered under Section 12(b) of the Exchange Act are the Common Stock (PTIX) and the Common Stock Warrants (PTIXW), both trading on OTC Markets. There is no mention of uplisting, delisting, or any adjustment to the capital structure. -
No Changes in Management or Control:
There are no disclosures regarding changes in the company’s executive leadership, board composition, or control arrangements. -
Not a Shell Company:
The company is not registered as a shell company, which is relevant for investors concerned about compliance and transparency. -
Routine Compliance:
This filing is a standard requirement under Section 13 or 15(d) of the Securities Exchange Act of 1934.
Potential Price Sensitivity
No Immediate Price-Sensitive News:
After a thorough review of the filing, there are no announcements or disclosures that would be considered material or likely to move the share price of Protagenic Therapeutics, Inc. at this time. Investors should note that this Form 8-K is largely procedural and does not indicate any significant corporate developments, financial performance updates, or strategic changes.
Summary
The February 3, 2026, Form 8-K filing by Protagenic Therapeutics, Inc. is a routine SEC compliance document. It does not contain any news or events that are likely to impact the company’s share price or are otherwise material for investors. The company continues to operate under its current structure and management, with its common stock and warrants listed on the OTC Markets under the symbols PTIX and PTIXW.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult with a financial advisor before making investment decisions. The information is based on public regulatory filings as of the stated date and may not reflect subsequent developments.
